FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006448500> ?p ?o ?g. }

• W3006448500 endingPage "417" @default.
• W3006448500 startingPage "410" @default.
• W3006448500 abstract "To analyze prostatic-specific antigen density (PSAD) according to the Prostate Imaging Reporting and Data System (PIRADSv.2) score, in order to determine how it should be used. This correlative series considered 952 men with prostatic-specific antigen >3 ng/ml and/or abnormal digital rectal examination who were subjected to prostatic biopsy (PB) between 2016 and 2017. Of these men, 768 had no previous 5-α-reductase inhibitor use or history of prostate cancer (CaP) and had previously undergone 3-T multiparametric magnetic resonance imaging (mpMRI). In this sample, 549 men were biopsy-naïve and 219 had at least 1 previous negative PB. A 12-core transrectal ultrasound-guided PB was performed in all participants, as well as at least 2-core targeted biopsies of every detected lesion with a PIRADSv.2 score ≥3. Significant CaP (sCaP) was defined as an International Society of Uropathologist grade >1 or tumor length >4 mm. The overall CaP detection was 41.7%, with sCaP detected in 37.4%. sCaP was detected in 4.3% of PIRADSv.2 <3, 21.5% of PIRADSv.2 =3, 56.6% of PIRADSv.2 =4, and 78.5% of PIRADSv.2 =5, (P < 0.001). Insignificant CaP detection ranged from 6.5% to 1.5% respectively (P = 0.099). PSAD was an independent predictor of sCaP (odds ratios 1.971, 95% confidence interval [1.633, 2.378], P <0.001) and mpMRI (OR 3.179, 95%CI [2.593, 4.950], P < 0.001). Age (P = 0.013), family history of CaP (P = 0.021), and the type of PB (initial vs. repeated, P < 0.001) were also independent predictors of sCaP. PSAD was determined by PIRADSv.2 (P = 0.013) and the presence of sCaP (P < 0.001). PSAD increased with PIRADSv.2 score, even in men with CaP (P < 0.001) and slightly in men without CaP (P = 0.019). The area under the curve for mpMRI increased from 0.830 to 0.869 when PSAD was associated, (P < 0.001). The area under the curve of PSAD decreased from 0.727 in men with a PIRADSv.2 score <3 to 0.706 in those with a score of 5. The efficacy of PSAD to detect sCaP decreases with PIRADSv.2. Predictors other than mpMRI and PSAD exist. Considering these conditions, independent predictors should be integrated in a nomogram and risk-calculator to personalize PB recommendation." @default.
• W3006448500 created "2020-02-24" @default.
• W3006448500 creator A5004617137 @default.
• W3006448500 creator A5009118055 @default.
• W3006448500 creator A5012233693 @default.
• W3006448500 creator A5016719534 @default.
• W3006448500 creator A5018364677 @default.
• W3006448500 creator A5025981932 @default.
• W3006448500 creator A5032597093 @default.
• W3006448500 creator A5055737222 @default.
• W3006448500 creator A5057473966 @default.
• W3006448500 creator A5079384088 @default.
• W3006448500 date "2020-05-01" @default.
• W3006448500 modified "2023-09-30" @default.
• W3006448500 title "Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result" @default.
• W3006448500 cites W1827911007 @default.
• W3006448500 cites W2002327210 @default.
• W3006448500 cites W2003805842 @default.
• W3006448500 cites W2039511031 @default.
• W3006448500 cites W2060032424 @default.
• W3006448500 cites W2080725537 @default.
• W3006448500 cites W2124539070 @default.
• W3006448500 cites W2288851487 @default.
• W3006448500 cites W2295402589 @default.
• W3006448500 cites W2395925941 @default.
• W3006448500 cites W2492616481 @default.
• W3006448500 cites W2577453388 @default.
• W3006448500 cites W2591284335 @default.
• W3006448500 cites W2602602904 @default.
• W3006448500 cites W2604451932 @default.
• W3006448500 cites W2801556653 @default.
• W3006448500 cites W2801986443 @default.
• W3006448500 cites W2805770535 @default.
• W3006448500 cites W2805982663 @default.
• W3006448500 cites W2893199713 @default.
• W3006448500 cites W2905856158 @default.
• W3006448500 cites W2911188335 @default.
• W3006448500 cites W2932565984 @default.
• W3006448500 doi "https://doi.org/10.1016/j.urolonc.2019.12.013" @default.
• W3006448500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32067845" @default.
• W3006448500 hasPublicationYear "2020" @default.
• W3006448500 type Work @default.
• W3006448500 sameAs 3006448500 @default.
• W3006448500 citedByCount "10" @default.
• W3006448500 countsByYear W30064485002021 @default.
• W3006448500 countsByYear W30064485002022 @default.
• W3006448500 countsByYear W30064485002023 @default.
• W3006448500 crossrefType "journal-article" @default.
• W3006448500 hasAuthorship W3006448500A5004617137 @default.
• W3006448500 hasAuthorship W3006448500A5009118055 @default.
• W3006448500 hasAuthorship W3006448500A5012233693 @default.
• W3006448500 hasAuthorship W3006448500A5016719534 @default.
• W3006448500 hasAuthorship W3006448500A5018364677 @default.
• W3006448500 hasAuthorship W3006448500A5025981932 @default.
• W3006448500 hasAuthorship W3006448500A5032597093 @default.
• W3006448500 hasAuthorship W3006448500A5055737222 @default.
• W3006448500 hasAuthorship W3006448500A5057473966 @default.
• W3006448500 hasAuthorship W3006448500A5079384088 @default.
• W3006448500 hasConcept C121608353 @default.
• W3006448500 hasConcept C126322002 @default.
• W3006448500 hasConcept C126838900 @default.
• W3006448500 hasConcept C126894567 @default.
• W3006448500 hasConcept C143409427 @default.
• W3006448500 hasConcept C156957248 @default.
• W3006448500 hasConcept C2775934546 @default.
• W3006448500 hasConcept C2776235491 @default.
• W3006448500 hasConcept C2780101318 @default.
• W3006448500 hasConcept C2780192828 @default.
• W3006448500 hasConcept C2781217009 @default.
• W3006448500 hasConcept C2781406297 @default.
• W3006448500 hasConcept C2989005 @default.
• W3006448500 hasConcept C44249647 @default.
• W3006448500 hasConcept C71924100 @default.
• W3006448500 hasConceptScore W3006448500C121608353 @default.
• W3006448500 hasConceptScore W3006448500C126322002 @default.
• W3006448500 hasConceptScore W3006448500C126838900 @default.
• W3006448500 hasConceptScore W3006448500C126894567 @default.
• W3006448500 hasConceptScore W3006448500C143409427 @default.
• W3006448500 hasConceptScore W3006448500C156957248 @default.
• W3006448500 hasConceptScore W3006448500C2775934546 @default.
• W3006448500 hasConceptScore W3006448500C2776235491 @default.
• W3006448500 hasConceptScore W3006448500C2780101318 @default.
• W3006448500 hasConceptScore W3006448500C2780192828 @default.
• W3006448500 hasConceptScore W3006448500C2781217009 @default.
• W3006448500 hasConceptScore W3006448500C2781406297 @default.
• W3006448500 hasConceptScore W3006448500C2989005 @default.
• W3006448500 hasConceptScore W3006448500C44249647 @default.
• W3006448500 hasConceptScore W3006448500C71924100 @default.
• W3006448500 hasIssue "5" @default.
• W3006448500 hasLocation W30064485001 @default.
• W3006448500 hasOpenAccess W3006448500 @default.
• W3006448500 hasPrimaryLocation W30064485001 @default.
• W3006448500 hasRelatedWork W1592081815 @default.
• W3006448500 hasRelatedWork W1967456449 @default.
• W3006448500 hasRelatedWork W1980188241 @default.
• W3006448500 hasRelatedWork W2099948048 @default.
• W3006448500 hasRelatedWork W2102167265 @default.
• W3006448500 hasRelatedWork W2143331076 @default.

• next